MAGNET Program

Magnet Biomedicine is a biotechnology company focused on the discovery and development of a new class of molecular glues called TrueGlues. The company's proprietary TrueGlue discovery platform uses human genetics and proteomics to rationally select and design small molecules that induce proximity between target proteins and 'presenter' proteins. Unlike traditional molecular glues that primarily focus on protein degradation, Magnet's approach aims to unlock a broader range of biological mechanisms to address historically undruggable targets. The company is initially targeting indications in oncology, immunology, and cardiovascular disease.